Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating income | -$377K | -$2.43M | -$10.1M | -$28.2M | -$39.5M | -$30.8M | -$20.2M |
| Net income | -$847K | -$3.78M | -$8.52M | -$28.3M | -$39.3M | -$29.9M | -$19.9M |
| EPS (diluted) | -$0.31 | -$1.24 | -$0.58 | — | — | — | — |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$218K | -$4.07M | -$10.7M | -$19.0M | -$28.3M | -$33.5M | -$24.6M |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $193.00 | $8.76M | $29.7M | $18.5M | $23.4M | $13.5M | $14.4M |
| Total assets | $2.60K | $8.76M | $31.4M | $18.9M | $23.7M | $15.5M | $15.9M |
| Total liabilities | $6.81M | $3.30M | $2.72M | $6.49M | $18.0M | $14.7M | $7.28M |
| Shareholders' equity | -$6.81M | $5.47M | $28.7M | $17.6M | $5.72M | $813K | $8.65M |
| Retained earnings | -$54.5M | -$58.3M | -$66.8M | -$85.9M | -$134M | -$164M | -$184M |
| Shares (wtd avg diluted) | 2.60M | 9.23M | 14.8M | 19.5M | 23.8M | 1.69M | 3.63M |
Every figure is extracted from REVIVA PHARMACEUTICALS HOLDINGS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.